Bionano Genomics AI Price Prediction

Bionano Genomics is currently unprofitable, as reflected in its negative EPS and PE ratio. The magnitude of the loss per share suggests a business still far from breakeven, with substantial execution and financing risk. Without evidence of improving margins or clear visibility to profitability, the financial profile is a headwind for the stock.

• Negative EPS of -12.77 and a PE ratio of -0.12 indicate ongoing and significant losses, with no current earnings support for the valuation.
• The scale of the per-share loss implies high cash burn and dependence on external capital (equity or debt) to fund operations.
• Absent data showing improving revenue growth, gross margin expansion, or narrowing net losses, the financial trajectory appears structurally weak and remains a key risk for equity holders.

At $1.51, Bionano Genomics trades well below its 200-day moving average of $2.75, signaling a sustained downtrend. The RSI at 32.05 is near oversold territory, suggesting selling pressure has been strong, though it could also precede short-term bounces. Overall, the technical setup points to a weak trend with limited confirmation of a durable reversal.

• Price ($1.51) is significantly under the 200-day moving average ($2.75), indicating a prolonged bearish trend and damaged longer-term sentiment.
• RSI of 32.05 is close to the oversold threshold (30), reflecting persistent selling; this can create conditions for short-term technical rebounds but does not by itself reverse the broader downtrend.
• Despite only a modest 1.3% decline over the last month, the large gap to the 200-day moving average suggests that prior drawdowns have been substantial and that the stock remains technically weak.

Bionano Genomics’ stock currently reflects a combination of weak fundamentals and a technically damaged chart, with the share price well below its long-term moving average and the company still meaningfully unprofitable. Alternative data are largely flat and do not provide a strong counterbalance to the financial and technical risks. Overall, the setup leans bearish, with any potential upside likely dependent on future fundamental catalysts not visible in the current data.

• Persistent unprofitability and a large negative EPS, combined with a price far below the 200-day moving average, weigh heavily on the equity story.
• Alternative data show stability rather than growth, offering limited evidence of accelerating commercial traction that could offset financial and technical concerns.